← Evidence map

ArticleFrontiers in medicine2026

Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study.

Tingting Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study. | OpenQuestion